James P. Lugo

James P. Lugo
Inter Health · Research & Business Development

Doctor of Philosophy, Immunology

About

7
Publications
6,787
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
227
Citations
Citations since 2017
0 Research Items
178 Citations
2017201820192020202120222023010203040
2017201820192020202120222023010203040
2017201820192020202120222023010203040
2017201820192020202120222023010203040
Learn about citations on ResearchGate
Additional affiliations
April 2011 - July 2015
Inter Health
Inter Health
  • R&D
  • Benicia, United States
Position
  • Managing Director

Publications

Publications (7)
Table 1 . Number of subjects stratified based on medication usage
Table 2 . Demographic and baseline characteristics of metformin using...
Impact of chromium dinicocysteinate supplementation on inflammation, oxidative stress, and insulin resistance in type 2 diabetic subjects: An exploratory analysis of a randomized, double-blind, placebo-controlled study
Article
Full-text available
  • Sep 2016
Background: Chromium dinicocysteinate (CDNC) is a unique chromium complex consisting of chromium, niacin, and L-cysteine. Previous preclinical and clinical studies support the safety and efficacy of CDNC in modulating oxidative stress, vascular inflammation, and glycemia in type 2 diabetes. Objective: Herein, we report the results of several exp...
Fig. 1 Enrollment and randomization flow chart 
Table 3 Demographic and baseline characteristics of the trial subjects 
Table 4 Change in total WOMAC score from baseline 
Table 5 Stratified analysis for change in total WOMAC score based on...
+4 Table 6 Reduction in mean WOMAC subscores in placebo, GC and UC-II...
Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: A multicenter randomized, double-blind, placebo-controlled study
Article
Full-text available
  • Jan 2016
Background Undenatured type II collagen (UC-II) is a nutritional supplement derived from chicken sternum cartilage. The purpose of this study was to evaluate the efficacy and tolerability of UC-II for knee osteoarthritis (OA) pain and associated symptoms compared to placebo and to glucosamine hydrochloride plus chondroitin sulfate (GC). Methods One...
Table 1 Dose levels and assignment of animals. 
Table 2 Incidence of positive effects, severity and reversibility of...
Table 4 Summary of mean hematology values at day 91. 
Safety and toxicological evaluation of Meratri®: An herbal formulation for weight management
Article
Full-text available
  • Feb 2015
Meratrim is a unique dietary ingredient consisting of extracts from Sphaeranthus indicus flower heads and Garcinia mangostana fruit rind. Clinical studies have demonstrated that Meratrim is effective and well-tolerated in weight management. Herein we assessed the broad spectrum safety of Meratrim in a battery of in vitro and animal toxicological st...
Table 2 Protocol summary
Table 3 Representative list of prohibited medications* by category
Table 4 Demographic and baseline characteristics of enrolled subjects
Table 6 Summary of analysis of adverse events (AEs) in all subjects
+3 Sequence of study procedures at a typical clinic visit.
Undenatured type II collagen (UC-II®) for joint support: A randomized, double-blind, placebo-controlled study in healthy volunteers
Article
Full-text available
  • Oct 2013
UC-II contains a patented form of undenatured type II collagen derived from chicken sternum. Previous preclinical and clinical studies support the safety and efficacy of UC-II in modulating joint discomfort in osteoarthritis and rheumatoid arthritis. The purpose of this study was to assess the efficacy and tolerability of UC-II in moderating joint...
Proliferation of thymic stem cells with and without receptors for interleukin 2. Implications for intrathymic antigen recognition
Article
  • May 1985
We have tested the dividing cells in the mouse thymus for expression of interleukin 2 (IL-2) receptors (IL-2-R) using the rat monoclonal antibody 7D4. A discrete subpopulation of the lymphoblasts clearly expressed IL-2-R at levels comparable to those on mitogen-activated peripheral T cells. This subpopulation, however, represented a small minority...

Network

Cited
View All
Cited By
View All